ARCHIVES

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

This article is from The Cancer Letter archive.

Vol. 29 No. 6 | June 30, 2006

Download PDF Visit The Full Archive

Related Articles

Two-Point Rise In PSA Signals High-Risk Prostate Cancer

August 26, 2005

Bloch Dissatisfied With PDQ, Offers $1 Million To fund “Tailored” Treatment Data To Physicians

November 13, 1987

AACR thanks NCI for funds, provides platform for von Eschenbach’s 2015 goal. Also 2015 goal not a dream, but a vision, NCI director says.

July 18, 2003

“What Is Good For NCI Is Good For NIH,” Broder Says In Address

January 13, 1995

Xeloda + Oxaliplatin Compares To FOLFOX-4 In First Line

January 30, 2009

Organ Site Program Fate On Line, Gets Review Next Week

November 20, 1981